Showing 5841-5850 of 9076 results for "".
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of pa
- 2020 RealSelf Sun Safety Report: Majority of Americans Don’t Use Sunscreen Dailyhttps://practicaldermatology.com/news/realself-sun-safety-report-majority-of-americans-dont-use-sunscreen-daily/2460381/The recently released 2020 RealSelf Sun Safety Report found that 62 percent of Americans use anti-aging products as part of their daily skincare routine, but only 11 percent wear sunscreen daily and 46 percent never wear
- COVID-19 By the Numbers: May 5 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-may-5-edition/2460375/Sixteen states have significantly reduced COVID-19 restrictions, while 18 have somewhat reduced restrictions, a new analysis from WalletHub reveals. The easing comes as the US reports nearly 70,000 COVI
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/
- COVID-19 Update: AAD, Others React to Potential Shortage of Malaria and Arthritis Drugshttps://practicaldermatology.com/news/covid-19-update-aad-others-react-to-potential-shortage-of-malaria-and-arthritis-drugs-1/2460320/The American Academy of Dermatology along with the Lupus Foundation of America, the American College of Rheumatology, and the Arthritis Foundation are concerned about hydroxychloroquine and chloroquine shortages and how it will impact patients with autoimmune diseases. The groups sent a
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- MyHealthTeams, Global Vitiligo Foundation Team Up to Create New Social Networkhttps://practicaldermatology.com/news/myhealthteams-global-vitiligo-foundation-team-up-to-create-new-social-network/2460293/
- Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impacthttps://practicaldermatology.com/news/post-market-price-changes-alone-account-for-most-recent-spending-growth-for-biologics-and-rebates-have-little-impact/2460214/Annual spending on biologics by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016, according to research presented
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- Meet Ortho Derm’s 2019 Aspire Higher Scholarship Winnershttps://practicaldermatology.com/news/meet-ortho-derms-2019-aspire-higher-scholarship-winners/2460177/Ortho Dermatologics